The trajectory of the erectile dysfunction drug presents a intricate picture for shareholders. While the initial launch generated massive profits, the expiration of its patent opened the door to cheaper competitors, https://redhotbookmarks.com/story21587269/sildenafil-and-pharma-a-risky-opportunity